Blueberries Medical (BBM) AI Stock Analysis

• Market Cap: C$7.43M
• Dividend Yield: N/A
• Average Volume (3M): 5.76K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.86
• Revenue Growth: 55.74%
• EPS Growth: -27.59%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 495,090,100
• 10 Day Avg. Volume: 100
• 30 Day Avg. Volume: 5,759
• PEG Ratio: 0.06
• Price to Book (P/B): 4.78
• Price to Sales (P/S): 8.46
• P/FCF Ratio: -5.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.01 ▼(-50.00% Downside)

The overall stock score is primarily impacted by financial performance challenges and bearish technical indicators. The company's ongoing losses and cash flow issues are significant risks, and the technical analysis suggests continued downward pressure. The lack of positive valuation metrics further weighs on the score.

Positive Factors

Revenue Growth

The company has demonstrated strong revenue growth of over 52%, indicating increasing demand for its products and potential market expansion.

Low Leverage

Low leverage provides financial stability and flexibility, reducing risk and allowing the company to invest in growth opportunities without excessive debt burden.

Market Position in Medical Cannabis

BBM's focus on cannabinoid-based therapies positions it well in the growing medical cannabis market, with potential for long-term growth as demand for alternative therapies increases.

Negative Factors

Profitability Challenges

Ongoing profitability challenges, despite revenue growth, indicate operational inefficiencies that could hinder long-term financial health and investor confidence.

Negative Cash Flow

Negative cash flow reflects ongoing cash burn issues, which can limit the company's ability to invest in growth and sustain operations without external funding.

Low Profit Margins

Negative profit margins indicate that the company is not efficiently converting revenue into profit, which could impact long-term sustainability and competitiveness.

Blueberries Medical Business Overview & Revenue Model

Company Description

Blueberries Medical (BBM) is a leading player in the healthcare sector, specializing in the cultivation, production, and distribution of high-quality medical cannabis products. The company focuses on leveraging advanced agricultural techniques and cutting-edge technology to deliver a range of cannabinoid-based therapies aimed at various medical conditions. BBM operates in both the cultivation and pharmaceutical sectors, providing innovative solutions that cater to the growing demand for natural health alternatives.

How the Company Makes Money

Blueberries Medical generates revenue primarily through the sale of its medical cannabis products to licensed distributors, pharmacies, and healthcare providers. The company has established key revenue streams from its cultivation operations, where it produces high-quality cannabis that is sold in bulk. Additionally, BBM generates income from its proprietary formulations and branded products, which are marketed directly to consumers through online platforms and retail partnerships. The company also benefits from strategic partnerships with healthcare institutions and research organizations, enabling it to explore new therapeutic applications and expand its market reach. Furthermore, BBM may engage in licensing agreements for its intellectual property, diversifying its income sources.

Blueberries Medical Financial Statement Overview

Summary

Blueberries Medical faces substantial challenges in achieving profitability and positive cash flow. Despite revenue growth, the company struggles with operational efficiency and cash generation. The balance sheet is stable with low leverage, but persistent losses and cash flow issues pose significant risks.

Income Statement

Blueberries Medical has shown some progress in revenue growth but continues to face significant profitability challenges. The gross profit margin has fluctuated but remains low, indicating efficiency issues. The net profit margin is negative, highlighting ongoing losses. Despite revenue growth, the EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet indicates a relatively stable equity position, although it has faced declining total assets over recent years. The debt-to-equity ratio is low, suggesting conservative leverage use. However, the return on equity is negative due to net losses, which is a concern. The equity ratio is healthy, showing good asset financing through equity.

Cash Flow

Cash flow analysis reveals significant negative operating cash flow and free cash flow, reflecting ongoing cash burn issues. The free cash flow to net income ratio is concerning, as it indicates inefficiencies in converting net income into cash. The operating cash flow to net income ratio is negative, showing issues in operational cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	413.97K	471.41K	288.27K	235.45K	138.75K	65.98K
Gross Profit	128.09K	164.52K	84.22K	-17.72K	-245.45K	62.40K
EBITDA	-1.44M	-1.04M	-1.22M	-811.47K	-4.05M	-4.11M
Net Income	-1.55M	-1.15M	-1.64M	-1.47M	-5.15M	-4.94M
Balance Sheet
Total Assets	1.18M	1.38M	2.42M	3.35M	3.59M	7.27M
Cash, Cash Equivalents and Short-Term Investments	23.81K	66.08K	818.16K	1.41M	1.34M	306.51K
Total Debt	11.02K	11.44K	12.80K	1.34M	1.44M	1.49M
Total Liabilities	409.76K	545.61K	470.72K	1.89M	2.16M	3.38M
Stockholders Equity	766.98K	834.81K	1.95M	1.47M	1.43M	3.89M
Cash Flow
Free Cash Flow	-1.31M	-796.85K	-1.35M	-1.47M	-1.73M	-3.00M
Operating Cash Flow	-1.31M	-796.85K	-1.33M	-1.47M	-1.68M	-2.39M
Investing Cash Flow	-3.76K	9.00K	382.92K	101.94K	-48.77K	-611.04K
Financing Cash Flow	1.05M	-1.95K	539.10K	1.35M	2.77M	783.92K

Blueberries Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.01, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.04 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BBM.

Blueberries Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHB	56 Neutral	C$6.88M	-8.53	-17.81%	―	13.01%	-2445.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATLE	50 Neutral	C$55.65M	-2.76	-19.76%	―	26.91%	81.01%
IMCC	45 Neutral	$7.71M	-1.87	-93.87%	―	-0.74%	81.49%
CANB	44 Neutral	C$3.46M	-4.17	-11.42%	―	-5.87%	-239.53%
BBM	41 Neutral	C$7.43M	-4.05	-150.44%	―	55.74%	-27.59%